AFP Clinical Answers
COVID-19 and Remdesivir, Insulin Analogues, Opioid Use Disorder, Urinary Incontinence
Am Fam Physician. 2020 Jul 1;102(1):14.
Is remdesivir effective for patients who are hospitalized with COVID-19?
The Adaptive COVID-19 Treatment Trial took place at 60 different sites across the United States, Germany, Denmark, United Kingdom, Greece, Korea, Mexico, Spain, and Japan. The researchers randomized 1,063 patients who were hospitalized with coronavirus disease 2019 (COVID-19) and evidence of lower respiratory tract involvement to receive remdesivir (n = 538; 200 mg intravenously on day 1 and then 100 mg intravenously per day for up to 10 days or hospital discharge) or matching placebo infusion (n = 521). In mid-April, the primary end point was switched from mortality to time to recovery.
The time to recovery was significantly faster in the group treated with remdesivir than in those receiving placebo (11 days vs. 15 days; P < .001). There was also a trend toward a lower 14-day mortality rate in the remdesivir group (7.1% vs. 11.9%), but this was not statistically significant. If the mortality difference were significant, this would translate to a number needed to treat of 21. Projecting statistically, it is likely the study would have needed to continue for one to two weeks to accrue enough patients and events for the mortality data to become statistically significant. The rate of serious adverse events in the patients treated with remdesivir was slightly lower (21.1%) than in those receiving placebo (27.0%).
Are long-acting insulin analogues more effective than NPH insulin for type 2 diabetes mellitus?
NPH insulin use leads to fewer episodes of severe hypoglycemia than long-acting analogues (glargine [Lantus] and detemir [Levemir]) according to a large observational study, and it is less than one-half the cost. In adults with type 2 diabetes mellitus, NPH is a cost-effective alternative to insulin analogues.
When should adults be screened for opioid use disorder?
Expert guidelines recommend that all
Copyright © 2020 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions